| # | Drug | Count |
|---|---|---|
| 0 | CYCLOPHOSPHAMIDE | 8229 |
| 1 | CYCLOPHOSPHAMIDE FOR INJECTION | 8229 |
| 2 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 8229 |
| 3 | RITUXIMAB | 7956 |
| 4 | PREDNISONE | 7846 |
| 5 | DEXAMETHASONE | 7527 |
| 6 | DEXAMETHASONE 1.5 MG | 7516 |
| 7 | BEVACIZUMAB | 7448 |
| 8 | DOXORUBICIN | 6613 |
| 9 | CARBOPLATIN | 6172 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | TISLELIZUMAB-JSGR | 80 | 0.3571 |
| 1 | DATOPOTAMAB DERUXTECAN | 256 | 0.2980 |
| 2 | SACITUZUMAB GOVITECAN | 1368 | 0.2830 |
| 3 | TAFASITAMAB-CXIX | 239 | 0.2638 |
| 4 | BELINOSTAT | 77 | 0.2151 |
| 5 | POLATUZUMAB VEDOTIN | 2064 | 0.2023 |
| 6 | TAZEMETOSTAT | 305 | 0.1880 |
| 7 | GLOFITAMAB | 486 | 0.1794 |
| 8 | PEMIGATINIB | 144 | 0.1688 |
| 9 | TRIFLURIDINE AND TIPIRACIL | 1795 | 0.1659 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 17611 |
| 1 | Kinase Inhibitor [EPC] | 15628 |
| 2 | Nucleoside Metabolic Inhibitor [EPC] | 14282 |
| 3 | Platinum-based Drug [EPC] | 13602 |
| 4 | Alkylating Drug [EPC] | 11684 |
| 5 | CD20-directed Cytolytic Antibody [EPC] | 8766 |
| 6 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 8232 |
| 7 | Nonsteroidal Anti-inflammatory Drug [EPC] | 6520 |
| 8 | Microtubule Inhibitor [EPC] | 6108 |
| 9 | Topoisomerase Inhibitor [EPC] | 4863 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD38-directed Cytolytic Antibody [EPC] | 909 | 0.1553 |
| 1 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 494 | 0.1221 |
| 2 | Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] | 73 | 0.1213 |
| 3 | Interleukin-5 Antagonist [EPC] | 74 | 0.1076 |
| 4 | Endoglycosidase [EPC] | 188 | 0.1015 |
| 5 | CD25-directed Cytotoxin [EPC] | 1 | 0.1000 |
| 6 | Protease Activator [EPC] | 11 | 0.0853 |
| 7 | CD19-directed Chimeric Antigen Receptor [EPC] | 842 | 0.0829 |
| 8 | Provitamin D2 Compound [EPC] | 2407 | 0.0809 |
| 9 | Enzyme Stabilizer [EPC] | 86 | 0.0734 |